2 patents currently held
402 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Apr 2030. from the record
Of the 402 now held by other companies, 342 name Merck Sharp and Dohme LLC as their current owner, and 60 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Apr 2030
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Feb 2031 · High confidence
Also notable
Ends Apr 2030 · Medium confidence
Engineered ANTI-IL-23P19 Antibodies
US 8,404,813
The most cited patent in this portfolio, cited by 22 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031.
Method of Treating Solid Cancers with Pegylated IL-10
US 8,865,652
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Formerly held, still cited
Notable
Ends Jan 2028 · High confidence
Cited by 129 later US patents, top 5% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Merck Sharp & Dohme LLC
Also notable
Ends Jun 2027 · High confidence
Cited by 114 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Merck Sharp & Dohme LLC
Also notable
Ends Aug 2027 · High confidence
Cited by 71 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Celltaxis, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 26 terms have ended since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Engineered ANTI-IL-23P19 Antibodies | 1 in force | to Feb 2031 |
| Method of Treating Solid Cancers with Pegylated IL-10 | 1 in force | to Apr 2030 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,865,652 | Method of Treating Solid Cancers with Pegylated IL-10 held by Merck Sharp & Dohme Corp. In force · Medium confidence | In force | Medium confidence | |
| US 8,404,813 | Engineered ANTI-IL-23P19 Antibodies held by Merck Sharp & Dohme Corp. In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 402 patents in force now held by others · 934 patents ended · 448 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term